DATATRAK ONE? Enters Preclinical Trials Extending Leadership Across All Trial Phases - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
DATATRAK ONE? Enters Preclinical Trials Extending Leadership Across All Trial Phases Texas A&M Institute for Preclinical Studies (TIPS) enters Agreement


DATATRAK ONE® Enters Preclinical Trials Extending Leadership Across All Trial Phases

Texas A&M Institute for Preclinical Studies (TIPS) enters Agreement

PR Newswire

CLEVELAND, Feb. 4, 2014 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DTRK), a leader in cloud-based, unified eClinical® technologies and related services for the clinical trials industry, today announced Texas A&M Institute for Preclinical Studies (TIPS) will utilize the D ATATRAK ONE® software suite.

TIPS, a unit within the Texas A&M College of Veterinary Medicine & Biomedical Sciences, provides a unique resource serving the preclinical needs of academic researchers and leaders in the biomedical and pharmaceutical industry. Texas A&M has a longstanding reputation as a leader in higher education and research, with the College of Veterinary Medicine & Biomedical Sciences being one of the largest veterinary schools in the United States, and having a wealth of expertise in:

  • All major veterinary medical specialties
  • Surgical and non-surgical interventional techniques
  • Advanced imaging and diagnostics

"We have found D ATATRAK to be extremely easy to work with, and we look forward to using the technology to meet our needs," said Dr. Matt Miller, director of TIPS. "Collaborating with D ATATRAK will prove beneficial, as we continue to serve our Texas A&M University researchers, as well as the research and development enterprise within the biomedical and pharmaceutical industry."

"The efficiencies of D ATATRAK ONE® are impactful to every phase of the trial process," stated Laurence P. Birch, D ATATRAK Chairman of the Board and CEO. "TAMU is a leading veterinary medicine institution and the ideal partner for D ATATRAK as we extend our expertise to academic research.  From preclinical to post-approval, cost and time savings are realized leveraging our truly unified system to optimize each trial, across all phases, from Concept to Cure®."

Join D ATATRAK Thought Leaders:

Tweet: . @tamuvetmed partners with #D ATATRAK ONE® in #preclinical studies extending #EDC leadership http://bit.ly/1fq0e9r

About D ATATRAK
D ATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. D ATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via D ATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The D ATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina.

Contact D ATATRAK at marketing@datatrak.com, follow the discussion on Twitter at @DATATRAKInc, join us on LinkedIn for industry insights and visit http://www.datatrak.com to find out more about how D ATATRAK one optimizes the eClinical data process.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 13, 2013 announcing its results for the third quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

About Texas A&M
For more information about the Texas A&M College of Veterinary Medicine & Biomedical Sciences, please visit the website vetmed.tamu.edu or follow on Facebook.

SOURCE DATATRAK International, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here